Pursuant to section 4.11 of National Instrument 51-102, Calyx Bio-Ventures Inc.
(TSX VENTURE:CYX) ("Calyx" or the "Company") announces it has changed auditors
and has filed a reporting package at www.sedar.com with respect to the change of
auditor.


The reporting package contains the following documents:



--  an executed Notice of Change of Auditor; 
--  a letter to the former auditor, Ernst & Young, LLP ("E&Y); 
--  a letter from the successor auditor Dale Matheson Carr-Hilton Labonte
    LLP; 
--  a letter from the former auditor, E&Y; and 
--  a letter confirming that the above-listed documents have been reviewed
    by the Board of Directors of the Company. 



About Calyx 

Calyx Bio-Ventures Inc. (TSX VENTURE:CYX) is an agricultural technology company
which is developing early stage agriculture ventures. Calyx brings its depth of
experience, capital and other capacity including its proprietary intellectual
property to enhance plant yields. In addition to Calyx's position as a
shareholder of Agrisoma Biosciences Inc., a company which is producing a
non-food energy feedstock crop for bioenergy, Calyx is pursuing
agri-pharmaceutical opportunities in the MMPR (Marijuana for Medical Purposes
Regulations) and the agri-tech space. For further information about Calyx,
please visit www.calyxbio.com.


Forward-Looking Statements: This document contains certain forward-looking
statements concerning Calyx, as well as other expectations, plans, goals,
objectives, information or statements about future events, conditions, or
performance that may constitute "forward-looking statements" or "forward-looking
information" under applicable securities legislation. Such statements or
information involve substantial known and unknown risks and uncertainties,
certain of which are beyond Calyx's control. 


Such forward-looking statements or information are based on a number of
assumptions, which may prove to be incorrect.


Although Calyx believes that the expectations reflected in such forward-looking
statements or information are reasonable, undue reliance should not be placed on
forward-looking statements because Calyx can give no assurance that such
expectations will prove to be correct. Forward-looking statements or information
are based on current expectations, estimates and projections that involve a
number of risks and uncertainties which could cause actual results to differ
materially from those anticipated by Calyx and described in the forward-looking
statements or information.


The forward-looking statements or information contained in this news release are
made as of the date hereof and Calyx undertakes no obligation to update publicly
or revise any forward-looking statements or information, whether as a result of
new information, future events or otherwise unless so required by applicable
securities laws or the TSX Venture Exchange. The forward-looking statements or
information contained in this news release are expressly qualified by this
cautionary statement.


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Calyx Bio-Ventures Inc.
Don Konantz
President & CEO
604-649-5961
dkonantz@calyxbio.com


Calyx Bio-Ventures Inc.
Investor Relations:
Keir Reynolds
778-998-9242
kreynolds@calyxbio.com
www.calyxbio.com
Calyx Ventures (TSXV:CYX)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Calyx Ventures Charts.
Calyx Ventures (TSXV:CYX)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Calyx Ventures Charts.